Edwards Lifesciences Corp. paid rival Boston Scientific Corp. $180 million as part of a settlement to end long-standing patent disputes between the two medical device makers.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
What are key trends in the transparency compliance landscape? And, how are life sciences manufacturers tackling growing requirements
PwC’s annual R&D spending report showcases companies that stand out in the field of biotechnology.
GeoVax Labs and Enesi Pharma announced a collaboration to develop solid-dose needle-free vaccine formulations utilizing GeoVax’s novel MVA-VLP vaccine platform in combination with Enesi’s ImplaVax device and formulation technology.
EnClear Therapies – a new medical device company spun out from QurAlis – will focus developmental programs on targeting neurological diseases, including amyotrophic lateral sclerosis and progressive supranuclear palsy.
Boston Scientific exercised the company’s option to buy the remaining shares of Santa Rosa, Calif.-based Millipede for $325 million.
The U.S. Food and Drug Administration plans to meet with top-level executives of e-cigarette makers, the agency’s chief said, hinting that some companies seem to be backing away from commitments related to youth’s access to e-cigarettes.
A 2017 study found that more than 700 million adults and children worldwide are obese, calling it a “rising pandemic.”
The U.S. Food and Drug Administration approved a new protocol for a post-marketing study of Bayer AG’s Essure birth-control device, as the regulator seeks more information on the device’s safety.
For a while now there has been a heated debate surrounding hybrid and closed loop insulin systems.
An Olympus Corp. subsidiary pleaded guilty and agreed to pay $85 million to resolve charges of failure to file reports with U.S. regulators regarding infections connected to its duodenoscopes while continuing to sell the medical devices used to view the gastrointestinal tract.